An advisory committee to Japan’s Ministry of Health, Labour and Welfare (MHLW) has issued approval recommendations for a new batch of drugs including Dermavant Sciences Inc./JT Pharmaceuticals Inc/Torii Pharmaceutical Co. Ltd.’s Aryl hydrocarbon receptor (AhR) Vtama (tapinarof) for psoriasis vulgaris and atopic dermatitis, the latter being the global-first approval in this indication.
Other notable products receiving preliminary nods on 31 May included Novo Nordisk A/S’s Awiqli (once-weekly basal insulin icodec) for diabetes and